Ascendis axes IL-2 program in retreat from oncology expansion - Fierce Biotech

Ascendis axes IL-2 program in retreat from oncology expansion  Fierce Biotech

Illinois State 46-0 St. Xavier (IL) (2 Sep, 2018) Final Score - ESPN

Illinois State 46-0 St. Xavier (IL) (2 Sep, 2018) Final Score  ESPN

Facile induction of immune tolerance by an interleukin-2–TGFβ surrogate agonist - Nature

Facile induction of immune tolerance by an interleukin-2–TGFβ surrogate agonist  Nature

Maintenance results boost Nektar's case for IL-2 agonist in atopic dermatitis - FirstWord Pharma

Maintenance results boost Nektar's case for IL-2 agonist in atopic dermatitis  FirstWord Pharma

BLIMP1 negatively regulates IL-2 signaling in T cells - Science | AAAS

BLIMP1 negatively regulates IL-2 signaling in T cells  Science | AAAS

Aulos looks to Phase III for IL-2 mAb in NSCLC and melanoma - Clinical Trials Arena

Aulos looks to Phase III for IL-2 mAb in NSCLC and melanoma  Clinical Trials Arena

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC - CancerNetwork

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC  CancerNetwork

First-in-Class IL-2 Pathway Agonist Advances in AD - Dermatology Times

First-in-Class IL-2 Pathway Agonist Advances in AD  Dermatology Times

Intralesional IL-2 shows promise for patients with hard-to-treat cSCC - Hospital Healthcare Europe

Intralesional IL-2 shows promise for patients with hard-to-treat cSCC  Hospital Healthcare Europe

[ESMO 2025] GI Innovation’s IL-2 therapy shows tumor response in ICB-resistant cancers - koreabio...

[ESMO 2025] GI Innovation’s IL-2 therapy shows tumor response in ICB-resistant cancers  koreabiomed.com

Immunology & Cell Biology | ASI Journal - Wiley Online Library

Immunology & Cell Biology | ASI Journal  Wiley Online Library

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 tr...

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial  Nature

Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC - CancerNetwork

Novel IL-2 Therapy Combo Yields Initial Responses in Nonsquamous NSCLC  CancerNetwork

IL-9 and Blimp-1 protect the transcriptional identity of group 2 innate lymphocytes in allergic a...

IL-9 and Blimp-1 protect the transcriptional identity of group 2 innate lymphocytes in allergic asthma  Nature

Efficacy and safety of low-dose interleukin 2 for Behçet’s syndrome: a randomized, placebo-contro...

Efficacy and safety of low-dose interleukin 2 for Behçet’s syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial  Nature

An immune competent in vitro model of IL2 induced vascular leakage enables mechanistic insights a...

An immune competent in vitro model of IL2 induced vascular leakage enables mechanistic insights and evaluation of mitigation strategies  Nature

αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility ...

αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models  Nature

IL2Pepscan: A machine learning framework for predicting IL-2 inducing peptides and their identifi...

IL2Pepscan: A machine learning framework for predicting IL-2 inducing peptides and their identification across global viral proteomes  Nature

Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes - Nature

Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes  Nature

In Silico tool for predicting, designing and scanning IL-2 inducing peptides | Scientific Reports...

In Silico tool for predicting, designing and scanning IL-2 inducing peptides | Scientific Reports  Nature

Bispecific cytokine delivers for Innovent at last | ApexOnco - Clinical Trials news and analysis ...

Bispecific cytokine delivers for Innovent at last | ApexOnco - Clinical Trials news and analysis  Oncology Pipeline

Long-acting IL-2 release from pressure-fused biomineral tablets promotes antitumor immune respons...

Long-acting IL-2 release from pressure-fused biomineral tablets promotes antitumor immune response  Nature

PD-1 + IL-2 power couple: Wake up 'sleepy' T cells to turbo-charge cancer cures - EurekAlert!

PD-1 + IL-2 power couple: Wake up 'sleepy' T cells to turbo-charge cancer cures  EurekAlert!

Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study - medRxiv

Low-dose interleukin-2 for recurrent early pregnancy loss: a proof-of-concept study  medRxiv

CD2 targeted nanoparticles containing IL-2 mimic fetal-maternal tolerance of pregnancy by inducin...

CD2 targeted nanoparticles containing IL-2 mimic fetal-maternal tolerance of pregnancy by inducing synergistic TGF-β-producing NK cells and Tregs  Frontiers

Nektar says IL-2 pathway agonist rejected by Lilly succeeds in atopic dermatitis trial - FirstWor...

Nektar says IL-2 pathway agonist rejected by Lilly succeeds in atopic dermatitis trial  FirstWord Pharma

TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8 - Nature

TIM3-blockade synergizes with IL2 in alleviating intra-tumoral CD8  Nature

Authors of the air simulator "Korea. IL-2 Game Series" presented gameplay - the game will feature...

Authors of the air simulator "Korea. IL-2 Game Series" presented gameplay - the game will feature five seasons of the year  ixbt.games

Korea. IL-2 Series Reveals Post-Launch Content Roadmap - Bleeding Cool News

Korea. IL-2 Series Reveals Post-Launch Content Roadmap  Bleeding Cool News

Biomineral tablets for long-acting IL-2 immunotherapy - Nature

Biomineral tablets for long-acting IL-2 immunotherapy  Nature

Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficac...

Expression of an interleukin-2 partial agonist enhances regulatory T cell persistence and efficacy in mouse autoimmune models  Nature

Korea: IL-2 Series Preview and New Gameplay – A Promising Window Into the Early Jet Age - Simulat...

Korea: IL-2 Series Preview and New Gameplay – A Promising Window Into the Early Jet Age  Simulation Daily

New IL-2: Korea Gameplay Footage Released - FSElite

New IL-2: Korea Gameplay Footage Released  FSElite

Anti-cancer effect of interleukin-2 fused to flagellin expressed by tumor-targeting Salmonella - ...

Anti-cancer effect of interleukin-2 fused to flagellin expressed by tumor-targeting Salmonella  Nature

Korea: IL-2 Series Coming to Steam, Reveals Post-Launch Roadmap - Simulation Daily

Korea: IL-2 Series Coming to Steam, Reveals Post-Launch Roadmap  Simulation Daily

Genetic Leap receives FDA IND clearance for first-in-class, oral natural IL-2 modulator - PR News...

Genetic Leap receives FDA IND clearance for first-in-class, oral natural IL-2 modulator  PR Newswire

FDA Clears IND for GL-IL2-138 in Cancer and Beyond - Targeted Oncology

FDA Clears IND for GL-IL2-138 in Cancer and Beyond  Targeted Oncology

PD-1 x IL-2 antibody fusions: The next Keytruda competitors? - biocentury.com

PD-1 x IL-2 antibody fusions: The next Keytruda competitors?  biocentury.com

Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets - Fie...

Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets  Fierce Biotech

Interleukin-2 Inhibitors Clinical Trial Pipeline - GlobeNewswire

Interleukin-2 Inhibitors Clinical Trial Pipeline  GlobeNewswire

Korea. IL-2 Series - Official Pre-Order Trailer - IGN

Korea. IL-2 Series - Official Pre-Order Trailer  IGN

Nektar touts 'deepening clinical effect' of IL-2 agonist in atopic dermatitis - FirstWord Pharma

Nektar touts 'deepening clinical effect' of IL-2 agonist in atopic dermatitis  FirstWord Pharma

New Flight Sim Wants You Broke To Get Above Minimum Spec - DualShockers

New Flight Sim Wants You Broke To Get Above Minimum Spec  DualShockers

1C Game Studios Presents "Korea. IL-2 Series" and Talks About the Future of the Series - ixbt.games

1C Game Studios Presents "Korea. IL-2 Series" and Talks About the Future of the Series  ixbt.games

iLeukon’s mRNA IL-2 Therapy ILKN421H Achieves 80% Response Rate in Lung Cancer Trial - BioPharma ...

iLeukon’s mRNA IL-2 Therapy ILKN421H Achieves 80% Response Rate in Lung Cancer Trial  BioPharma APAC

Adding low-dose IL-2 to riluzole may improve survival in ALS - ALS News Today

Adding low-dose IL-2 to riluzole may improve survival in ALS  ALS News Today

Korea. IL-2 Series Releases New Gameplay Trailer - Bleeding Cool News

Korea. IL-2 Series Releases New Gameplay Trailer  Bleeding Cool News

Korea. IL-2 Series - IGN Africa

Korea. IL-2 Series  IGN Africa

Topline atopic dermatitis data showcase IL-2 modulator’s ‘incredibly novel’ mechanism - Healio

Topline atopic dermatitis data showcase IL-2 modulator’s ‘incredibly novel’ mechanism  Healio

1CGS Unveils Extended Support for Il-2 Sturmovik as Korea Hits Steam - DualShockers

1CGS Unveils Extended Support for Il-2 Sturmovik as Korea Hits Steam  DualShockers

9 biotechs making waves in interleukin therapeutics in 2025 - Labiotech.eu

9 biotechs making waves in interleukin therapeutics in 2025  Labiotech.eu

Flight sim "Korea. IL-2 series" developers dived to the ground and showed local residents - ixbt....

Flight sim "Korea. IL-2 series" developers dived to the ground and showed local residents  ixbt.games

Cubs Place Catcher Miguel Amaya on the 10-day IL, 2 Days After Activating Him - FOX Sports

Cubs Place Catcher Miguel Amaya on the 10-day IL, 2 Days After Activating Him  FOX Sports

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demon...

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients  Business Wire

Korea. IL-2 Series - IGN India

Korea. IL-2 Series  IGN India

IL-2 based cancer immunotherapies: an evolving paradigm - Frontiers

IL-2 based cancer immunotherapies: an evolving paradigm  Frontiers

Embracing precision medicine for advanced melanoma with tumor-infiltrating lymphocyte (TIL) thera...

Embracing precision medicine for advanced melanoma with tumor-infiltrating lymphocyte (TIL) therapy  Mayo Clinic

Korea. IL-2 Series - IGN France

Korea. IL-2 Series  IGN France

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, dou...

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial  The Lancet

"Korea. IL-2 series" creators told about aircraft customization - ixbt.games

"Korea. IL-2 series" creators told about aircraft customization  ixbt.games

Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective ...

Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends  Nature

PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function - Nature

PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function  Nature

Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor ...

Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor  PNAS

PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program - Nature

PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program  Nature

A distinct priming phase regulates CD8 T cell immunity by orchestrating paracrine IL-2 signals - ...

A distinct priming phase regulates CD8 T cell immunity by orchestrating paracrine IL-2 signals  Science | AAAS

Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and...

Proximity-enabled covalent binding of IL-2 to IL-2Rα selectively activates regulatory T cells and suppresses autoimmunity  Nature

Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits - Rockefeller U...

Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits  Rockefeller University Press

A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy -...

A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy  Nature

Engineering IL-2 for immunotherapy of autoimmunity and cancer - Nature

Engineering IL-2 for immunotherapy of autoimmunity and cancer  Nature

An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammat...

An in situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophages in renal cell carcinoma  Nature

Scientists Identify Key Biomarkers That May Predict Low-Dose IL-2 Treatment Efficacy in People wi...

Scientists Identify Key Biomarkers That May Predict Low-Dose IL-2 Treatment Efficacy in People with Systemic Lupus Erythematosus  Lupus Foundation of America

Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulator...

Astrocyte-targeted gene delivery of interleukin 2 specifically increases brain-resident regulatory T cell numbers and protects against pathological neuroinflammation  Nature

Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells - Nature

Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells  Nature

IL-2 treatment can be dangerous. How can drug firms tackle its challenges? - C&EN

IL-2 treatment can be dangerous. How can drug firms tackle its challenges?  C&EN

Regulatory T cells use heparanase to access IL-2 bound to extracellular matrix in inflamed tissue...

Regulatory T cells use heparanase to access IL-2 bound to extracellular matrix in inflamed tissue  Nature

Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates ...

Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8  Nature

A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T ...

A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells  Nature

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism - Nature

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism  Nature

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8 - Nature

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8  Nature

dendritic cell-derived IL-2 dictates CD4 - Nature

dendritic cell-derived IL-2 dictates CD4  Nature

A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo ...

A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells  Nature

Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulatio...

Costimulation blockade in combination with IL-2 permits regulatory T cell sparing immunomodulation that inhibits autoimmunity  Nature

De novo design of potent and selective mimics of IL-2 and IL-15 - Nature

De novo design of potent and selective mimics of IL-2 and IL-15  Nature

IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8 - Nature

IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8  Nature

T cells during infection requires MRTF/SRF-dependent gene expression and cytoskeletal dynamics - ...

T cells during infection requires MRTF/SRF-dependent gene expression and cytoskeletal dynamics  Nature

Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity - Nature

Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity  Nature

A promising option for unremitting ulcerative colitis: Low-dose IL-2 - Boston Children's Answers

A promising option for unremitting ulcerative colitis: Low-dose IL-2  Boston Children's Answers

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist...

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist  Nature

Dr Olson on Toxicities Associated With Lifileucel and IL-2 in Melanoma - OncLive

Dr Olson on Toxicities Associated With Lifileucel and IL-2 in Melanoma  OncLive

Examining the evidence for IL-2 in amyotrophic lateral sclerosis - The Lancet

Examining the evidence for IL-2 in amyotrophic lateral sclerosis  The Lancet

Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease - NEJM Evidence

Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease  NEJM Evidence

An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer - Nature

An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer  Nature

T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes - Nature

T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes  Nature

An engineered IL-2 partial agonist promotes CD8+ T cell stemness - Nature

An engineered IL-2 partial agonist promotes CD8+ T cell stemness  Nature

Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helpe...

Differential IL-2 expression defines developmental fates of follicular versus nonfollicular helper T cells  Science | AAAS

Regulatory T cells control toxicity in a humanized model of IL-2 therapy - Nature

Regulatory T cells control toxicity in a humanized model of IL-2 therapy  Nature

Restoring IL-2 to its cancer immunotherapy glory - Nature

Restoring IL-2 to its cancer immunotherapy glory  Nature

A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for p...

A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy  Nature

A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in...

A human orthogonal IL-2 and IL-2Rβ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia  Science | AAAS

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy - OncLive

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy  OncLive